ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
12 févr. 2024 16h16 HE
|
ResMed Inc.
ResMed launched AirCurve 11 bilevel devices to enhance sleep apnea device therapy options.
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
30 janv. 2024 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
29 janv. 2024 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
Sleep Apnea Oral Appliances Market Global Forecast to 2028 - Market Poised for Robust Growth to $0.9 Billion, Up from $0.4 Billion in 2023, Dominated by Mandibular Advancement Devices
11 janv. 2024 10h23 HE
|
Research and Markets
Dublin, Jan. 11, 2024 (GLOBE NEWSWIRE) -- The "Sleep Apnea Oral Appliances Market by Product (Mandibular Advancement Devices (MAD), Tongue-Retaining Devices (TRD)), Purchase Type...
Sleep Apnea Oral Appliances Market is Expected to Reach $0.9 Billion | MarketsandMarkets.
11 janv. 2024 07h30 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Sleep Apnea Oral Appliances market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing...
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
08 janv. 2024 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of...
Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
21 déc. 2023 08h30 HE
|
Apnimed, Inc.
-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- Part of a two-study...
Americas Sleep Apnea Market Worth $4.10 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
10 nov. 2023 05h46 HE
|
The Insight Partners
Pune, India, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Sleep apnea is a potentially serious sleep disorder where breathing repeatedly stops and starts. Such a condition prevents the patient's body from...
Global Sleep Apnea Market Analysis & Forecast to 2023-2033
08 nov. 2023 04h08 HE
|
Research and Markets
Dublin, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The "Global Sleep Apnea Market Analysis & Forecast to 2023-2033: Market By Product; By End-user; and by Region" report has been added to ...
Apnimed to Participate in Upcoming November Investor Conferences
06 nov. 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...